Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007

...lone), for the treatment of patients with metastatic or locally advanced breast cancer, in the U.S. In addition, the Japanese New Drug Application for ixabepilone was submitted in December, and the Marketing Authorization Application for ixabepilone is under review by the European Medicines Evaluation Agency fol...

Ixabepilone in Medical Technology

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from a Phase II study - which will be published in the August 10, 2007 issue of the Journal of Clinical Oncology (JCO) and are now available as an Early Release Article at <...

ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)

...apecitabine was the approved therapy, demonstrated response rates of 14% for capecitabine alone compared with 35% for capecitabine in combination with ixabepilone or 22% for capecitabine in combination with lapatinib. "This CoFactor data is encouraging to us as it surpasses the most recently reported response ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

...nning at 4:00 p.m. local time on Saturday, May 31, 2008. -- "Antitumor activity of anti-CTLA-4 monoclonal antibody (mAb) in combination with ixabepilone in preclinical tumor models" (Abstract #3048, Developmental Therapeutics: Immunotherapy Session) -- Poster presentation from 2:00 p.m. to 6:00...